Comprehensive Evaluation of Açaí Extracts: Cytotoxicity and Pharmacokinetic Induction in Human Hepatocytes

Study Background and Research Question

Botanical dietary supplements (BDS) such as Euterpe oleracea (açaí) have gained substantial popularity due to their marketed antioxidant, anti-inflammatory, and antiproliferative properties. However, limited data exist regarding their impact on drug-metabolizing enzymes and membrane transporters—critical determinants of pharmacokinetics and botanical-drug interactions. Given the widespread use of BDS and the global market's projected growth to $300 billion by 2028, concerns about safety, regulation, and pharmacological interactions have come to the fore. The reference study sought to address these gaps by systematically evaluating the cytotoxic potential and enzyme/transporter induction profile of açaí extracts in vitro, using human hepatocyte models (reference study).

Key Innovation from the Reference Study

The central innovation of this work lies in its comprehensive approach to assessing both the cytotoxicity and the capacity of açaí extracts to induce major drug-metabolizing cytochrome P450 (CYP450) enzymes and drug transporters in human hepatocytes. This dual focus is crucial for predicting not only direct hepatotoxic risks but also the potential for botanical-drug interactions that arise from altered pharmacokinetics. The research stands out by employing physiologically relevant in vitro models and a variety of extract preparations that reflect real-world consumer products, enhancing the translational relevance of its findings (internal article).

Methods and Experimental Design Insights

The study utilized sandwich-cultured human hepatocytes to evaluate cytotoxicity and the induction of CYP1A2, CYP2B6, CYP3A4, P-glycoprotein (P-gp), and organic anion transporting polypeptides (OATP1B1/B3) at the mRNA level via RT-qPCR. Four extract types—aqueous, acidic methanol, methanol, and ethanol—were prepared from both commercial açaí berry powder (Mountain Rose) and encapsulated products (Nature's Way, Natrol). This strategy ensured that the extracts tested mirrored those available to consumers. Cytotoxicity was measured using the CellTiter-Glo® luminescent assay, while functional transporter activity was assessed through intracellular probe accumulation in LS174T human colon carcinoma cells, a standard model for preliminary transporter screening. This multi-tiered approach allowed the researchers to dissect both viability effects and more subtle impacts on pharmacokinetic machinery.

Protocol Parameters

• Extract preparation: Aqueous, methanol, ethanol, and acidic methanol extractions from commercial açaí products to mimic consumer formulations.
• Cytotoxicity assay: CellTiter-Glo® luminescent assay in sandwich-cultured human hepatocytes, with time- and dose-dependent evaluation.
• Enzyme/transporter induction: RT-qPCR quantification of CYP1A2, CYP2B6, CYP3A4, P-gp, and OATP1B1/B3 mRNA following extract exposure.
• Transporter function: Intracellular probe accumulation assays in LS174T cells, targeting P-gp and OATP activity.
• Extract concentrations and exposure: Ranged to encompass physiologically relevant and supra-physiological levels for robust risk assessment.

Core Findings and Why They Matter

The data revealed a time- and dose-dependent reduction in hepatocyte viability for specific extracts, most notably the acidic methanol (MRAC), methanol (MRME), ethanol (MRET), and the acidic methanol extract from Natrol capsules (F4AC). This underscores the importance of extraction method and commercial source when assessing botanical supplement safety. Despite these cytotoxic effects, none of the extracts significantly induced mRNA expression of key CYP450 enzymes or transporters in hepatocytes. Complementary functional assays corroborated these findings, showing minimal impact on P-gp and OATP activity. These results suggest that while certain açaí extract preparations may pose direct cytotoxic risks, their potential to alter major drug metabolism or transporter-mediated pharmacokinetic pathways appears limited under the tested conditions (supporting evidence).

This distinction is critical for researchers and clinicians: cytotoxicity does not necessarily equate to altered drug disposition, and not all botanical extracts pose the same level of risk for pharmacokinetic interactions. The findings contribute to a more nuanced risk assessment framework for botanical-drug interaction studies, especially for compounds that undergo hepatic transport and metabolism.

Comparison with Existing Internal Articles

Multiple internal resources support and contextualize the present findings. For example, a related analysis (Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocytes) confirms the dose-dependent cytotoxicity and minimal induction risk across extract types. Another synthesis (Pravastatin Sodium: Unraveling Transporter Influence in Cholesterol Research) discusses how hepatic drug transporters like OATP1B1/B3 are pivotal for the pharmacokinetics of statins and other drugs, reinforcing why the absence of significant OATP induction by açaí is noteworthy for drug safety. These interlinked insights coalesce into a robust evidence base for researchers exploring transporter-mediated drug-botanical interactions.

Limitations and Transferability

While the study offers a systematic in vitro assessment, several limitations constrain direct clinical translation. First, the use of isolated human hepatocytes cannot fully recapitulate the complexity of in vivo hepatic architecture, systemic metabolism, or long-term exposure scenarios. The extracts represent common consumer products, but batch-to-batch variability and differences in phytochemical content may influence outcomes. Additionally, the research focused on mRNA expression and probe accumulation as proxies for functional induction, which, while informative, do not capture all post-translational or regulatory mechanisms. Thus, while the findings are highly relevant for in vitro risk assessment and preliminary screening, further in vivo and clinical studies are needed to define the real-world significance of açaí-induced cytotoxicity and interaction risk.

Research Support Resources

Researchers aiming to investigate transporter-mediated drug interactions, cholesterol biosynthesis inhibition, or competitive HMG-CoA reductase inhibitors can leverage validated molecular tools to support their workflows. Pravastatin sodium (SKU A4369), a highly selective HMG-CoA reductase inhibitor, is frequently utilized in hepatic transporter studies due to its defined sensitivity to OATP1B1-mediated uptake and LDL cholesterol reduction activity. Protocols may incorporate Pravastatin sodium at concentrations ranging from 0 to 100 μg/mL, with typical incubation times around 5 hours, as noted in the product information. These data facilitate reproducible pharmacokinetic and metabolic profiling in both cellular and animal models. APExBIO provides access to this reagent, supporting rigorous experimental control and translational research in cholesterol metabolism and drug interaction risk assessment.